About
Therapeutic Antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBoston & New England
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
3,841
By Phase
PHASE1: 2PHASE3: 1PHASE2/PHASE3: 2
By Status
COMPLETED: 2TERMINATED: 2ACTIVE_NOT_RECRUITING: 1NO_LONGER_AVAILABLE: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06523153Lead Sponsor
A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants
PHASE1Active, not recruiting
40 participants
Started: Aug 28, 2024 · Completed: May 31, 2025
NCT06039449Lead Sponsor
A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
PHASE3Completed
790 participants
Started: Sep 8, 2023 · Completed: Nov 19, 2024
NCT05791318Lead Sponsor
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants
PHASE1Completed
30 participants
Started: Mar 28, 2023 · Completed: May 8, 2024
NCT04805671Lead Sponsor
Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19
PHASE2/PHASE3Terminated
399 participants
Started: Jul 26, 2021 · Completed: Nov 3, 2022
NCT04859517Lead Sponsor
Evaluation of ADG20 for the Prevention of COVID-19
PHASE2/PHASE3Terminated
2,582 participants
Started: Apr 27, 2021 · Completed: Nov 4, 2022
Locations (1)
Headquarters
Waltham, MA, United States
Map
Loading map...